Promedior Announces Presentation of Preclinical Data at Association for Research in Vision & Ophthalmology Demonstrating PRM-151 (rhPTX-2) Reduces Neovascularization in Retinal Diseases

MALVERN, Pa.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, announced that data from preclinical studies of PRM-151 (recombinant human Pentraxin-2 (PTX-2)) were presented today at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Ft. Lauderdale, FL. In a poster entitled “PRM-151, recombinant human Pentraxin-2 (PTX-2), Suppresses Choroidal (CNV) and Retinal Neovascularization (RNV)”, Promedior and collaborators from The Johns Hopkins University Wilmer Eye Institute highlight the efficacy and utility of Pentraxin-2 in suppressing neovascularization in independent models of age-related macular degeneration (AMD) and diabetic retinopathy. Pentraxin-2 is a natural human protein that regulates the cell populations that control fibrosis, inflammation and pathologic neovascularization. In AMD, diabetic retinopathy, and macular edema, neovascularization is known to cause retinal damage which can result in visual impairment and progressive loss of vision.

Back to news